The size of the Asia Pacific Superdisintegrants Market was worth USD 63.57 million in 2020. IT is further estimated to be growing at a CAGR of 8.92% and value USD 97.45 million by 2025.
Tablet-based (Oral) drug administration is the most common way for drug delivery. Most of the common medicines are orally delivered. Excipients are the substances that make up the rest of the tablet other than the medicating substance itself, and it is used for long term stabilization and bulking up solid contents. One of the types of excipients is super disintegrants, which accelerate the dissociating and dissolving ability of the tablet in the presence of water for speedy drug delivery. Increasing healthcare expenditure and healthcare awareness among individuals has accounted for the growth of this market.
The main factors driving the market are developing new superdisintegrants in the pharmaceutical industry, the growing population of geriatric and pediatric patients, and the growing generic drugs market. However, the growth of the market is restricted by the declining financial investments in R&D fields. Although synthetic superdisintegrants have been the standard for many decades now, greater research into natural super disintegrants will motivate the future growth of the market.
This research report on the APAC Superdisintegrants Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Application:
By Therapeutic Area:
By Country:
Geographically, China is leading the market while India is in second place. Large populations and rapid medical advancements have assisted the dominance of China in the market. India is expected to grow the fastest due to increasing healthcare spending, rising healthcare infrastructure, and awareness.
Notable companies leading the Asia Pacific Superdisintegrants Market studied in this report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co., and Huber Corporation.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Natural Superdisintegrants
5.1.3 Synthetic Superdisintegrants
5.1.3.1 Modified Starch
5.1.3.2 Crospovidone
5.1.3.3 Modified Cellulose
5.1.3.4 Ion Exchange Resins
5.1.3.5 Calcium Silicates
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2 Application
5.2.1 Introduction
5.2.2 Capsules
5.2.3 Tablets
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 Therapeutic Area
5.3.1 Introduction
5.3.2 Gastrointestinal diseases
5.3.3 Neurological diseases
5.3.4 Oncology
5.3.5 Infectious Diseases
5.3.6 Cardiovascular Diseases
5.3.7 Haematological diseases
5.3.8 Inflammatory Diseases
5.3.9 Y-o-Y Growth Analysis, By Therapeutic Area
5.3.10 Market Attractiveness Analysis, By Therapeutic Area
5.3.11 Market Share Analysis, By Therapeutic Area
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Application
6.1.3.4 By Therapeutic Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Application
6.1.4.4 By Therapeutic Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Application
6.1.5.4 By Therapeutic Area
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Ashland
8.1.1 Overview
8.1.2 Product Type Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 BASF SE
8.3 FMC Corporation
8.4 JRS Pharma
8.5 DFE Pharma
8.6 Roquette
8.7 The Dow Chemical Company
8.8 Asahi Kasei Corporation
8.9 Nippon Soda Co.
8.10 Huber Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
